The GIP/GLP-1 receptor agonist reduced events in patients with HFpEF and obesity. John Mandrola questions whether it changed the disease trajectory, as the investigators claim.
theheart.org on Medscape
Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT?
